Place of Origin: | China |
Brand Name: | LiHui |
Certification: | Hplc ISO9001 |
Model Number: | 315-37-7 |
Minimum Order Quantity: | 100g |
---|---|
Price: | Negotiated |
Packaging Details: | Foil Bag |
Delivery Time: | 3-7days after received payment |
Payment Terms: | T/T, Western Union, MoneyGram |
Supply Ability: | 5000Kg Per Month |
CAS: | 315-37-7 | Color Or Appearance: | Add Muscle Reduced Fat |
---|---|---|---|
Packing Specification: | 100,000 Pieces Per Carton | Execution Standard: | USP42 |
Product Purity: | 99% | The Product Level: | In A Box |
Molecular Formula: | C26H40O3 | ||
High Light: | 10ml Testosterone Enanthate,250mg/ml Testosterone Enanthate,Test Enanthate 250 CAS 315-37-7 |
TE250 250mg/Ml, 10ml Methandrostenolone Testosterone Enanthate
Function main edit voice
Testosterone heptanoate can be used for reduced sexual function in men, delayed pubertal development in men, refractory anemia and advanced breast cancer in menopausal women. It can also be used for female functional uterine bleeding, climacteric syndrome, breast cancer and sexual organ cancer. Description: Injection: 1ml: 100mg, 1ml: 200mg.
Heptanoic acid testosterone
Testosterone heptanoate (2 sheets)
Suitable for male sexual dysfunction, dysplasia of sexual organs, infertility, cryptorchidism and no testosterone, etc. Can also be used for female functional uterine bleeding, menopausal syndrome, breast cancer and sexual organ cancer; Liver cirrhosis, aplastic anemia, osteoporosis and other wasting diseases.
Contraceptive efficacy
According to Xinhua News Agency, after efforts by Chinese scientists, the latest determination of testosterone heptanoate is the ideal contraceptive for men.
Testosterone heptanoate is a hormone ester, which can inhibit the pituitary gland, promote the release of gonadin, so as to reduce the endogenous testosterone secreted by testicular interstitial cells, and ultimately achieve the purpose of blocking spermatogenesis. The Institute of Animal Science of Chinese Academy of Sciences in the monkey experiment found that the injection of testosterone heptanoate once a week, a week after the monkey sperm cell apoptosis, to the fifth week of sperm cell apoptosis peak. The clinical trial of 308 volunteers also showed that testosterone heptanate pills were significantly more effective in Asian men than in caucasians. In the study, although sperm loss rates did not differ between races, Asians were more sensitive to hormone-induced inhibition of spermatogenesis than caucasians, with more than 95 percent of asians reaching spermatogenesis, while the drug was only effective in 40 to 70 percent of caucasians.
Does testosterone heptanate injection affect sex life in men? The vast majority of men who were injected with testosterone heptanate had sperm tests that showed anoospermia or severe oligospermia without affecting their sexual ability, the researchers said. After stopping the drug, all the subjects' normal spermatogenesis was restored without affecting sexual life.
Usage and usage edit voice
Heptanoic acid testosterone
Heptanoic acid testosterone
Intramuscular injection, usually 50 to 250mg every 2 to 4 weeks. The specific situation depends on the illness. Male sexual dysfunction, 100 ~ 400mg once, 1 ~ 2 times a day. For patients with wasting disease, 100 ~ 200mg once every 3 ~ 4 weeks. Breast cancer and sexual organ cancer, once 200mg, once every 2-3 weeks. Adverse reactions and attention: large doses or long-term use can cause water and sodium retention and edema. Women may have symptoms of masculinity after use.
Specification: Injection: 0 per dose. 1 g/ml. Medicare or not: Non-Medicare. Over-the-counter or not: Prescription. Other: pregnant women and prostate cancer is forbidden.
Drug function edit speech
Heptanoic acid testosterone
Heptanoic acid testosterone
Heptanoic acid testosterone inhibition in addition to cause sperm formation and sperm release barriers thereof, born of seminiferous tubule outline the arrangement of the endogenous sperm cells has become relatively loose, born sperm cells (mainly sperm cells and spermatocyte) between radial fracture (from basal surface toward the cavity surface), born in cavity of seminiferous tubule sperm cells rarely scattered off life. Loose arrangement of spermatogenic cells can be an important change that can result in spermatogenic cells exfoliating or abscission, but not in individual cells, but in clumps or groups of spermatogenic cells. This prompted us to further analyze whether the inhibition of human spermatogenesis caused by TESTOSTERONE heptanate was also accompanied by loose spermatogenic cell arrangement. This problem has either not attracted special attention in previous studies or has not been reported because of small changes.
Materials and methods for editing speech
Heptanoic acid testosterone
Heptanoic acid testosterone
Section: This study used a section previously used by one of the authors. In brief, 10 male reproductive volunteers (normal white adults 31 -- 46 years of age), 5 received testosterone heptanate injection intramusmally (200mg/ week) for 19 -- 24 weeks (testosterone group), and 5 did not receive treatment (control group). Testicular biopsy was performed, one testicular tissue block was obtained from each person, and each testicular tissue block was infiltrated and fixed by Bouin solution. Each testicular tissue block was embedded with hydroxyeth -- ylmethacrylate respectively. A 25m thick section was cut from each embedding block and stained with PAS and hematoxylin
Drug function edit speech
Heptanoic acid testosterone
Heptanoic acid testosterone
Heptanoic acid testosterone inhibition in addition to cause sperm formation and sperm release barriers thereof, born of seminiferous tubule outline the arrangement of the endogenous sperm cells has become relatively loose, born sperm cells (mainly sperm cells and spermatocyte) between radial fracture (from basal surface toward the cavity surface), born in cavity of seminiferous tubule sperm cells rarely scattered off life. Loose arrangement of spermatogenic cells can be an important change that can result in spermatogenic cells exfoliating or abscission, but not in individual cells, but in clumps or groups of spermatogenic cells. This prompted us to further analyze whether the inhibition of human spermatogenesis caused by TESTOSTERONE heptanate was also accompanied by loose spermatogenic cell arrangement. This problem has either not attracted special attention in previous studies or has not been reported because of small changes.
Materials and methods for editing speech
Heptanoic acid testosterone
Heptanoic acid testosterone
Section: This study used a section previously used by one of the authors. In brief, 10 male reproductive volunteers (normal white adults 31 -- 46 years of age), 5 received testosterone heptanate injection intramusmally (200mg/ week) for 19 -- 24 weeks (testosterone group), and 5 did not receive treatment (control group). Testicular biopsy was performed, one testicular tissue block was obtained from each person, and each testicular tissue block was infiltrated and fixed by Bouin solution. Each testicular tissue block was embedded with hydroxyeth -- ylmethacrylate respectively. A 25m thick section was cut from each embedding block and stained with PAS and hematoxylin.
Morphological quantitative research editing speech
Heptanoic acid testosterone
Heptanoic acid testosterone
OlympusBX50 biological microscope and stereological image system (jointly developed by north sichuan medical college, Beijing chi mat image technology co., LTD and sichuan university) were used to observe and measure the slices. First, observe with a 10× objective lens, select the first test field at the upper left corner of the section, and then use the computer-controlled electric loading platform to randomly select test fields along the X and Y axes. Microscopic images were taken with a digital camera (PanasonicWV). Cp410/6) were collected and transferred to a computer monitor for observation (magnification 268). The test system software was used to superimpose a rectangular test box at the lower left of the field of vision. According to the forbidden line rule, 20 round or oval spermospermous tubules with obvious lumen were selected from each section (that is, only those contours that were completely in the test box and crossed only with the right or/and above the test box were selected. The contours that were completely outside the test frame and had any cross with the left, below, left upward extension line or/with the right downward extension line were not selected), and the morphological characteristics of the selected spermatogenic tubules were carefully observed under a 20× objective lens, especially whether spermatogenic cells were loosely arranged. Loose arrangement is defined as the presence of at least two fissures in the spermatogenic tubule contour, and each fissures is a significant fissure between at least two adjacent spermatogenic cells and at least two other adjacent spermatogenic cells. The number of spermatogenic tubules with various characteristics was recorded and the ratio was calculated. Some data in this paper were expressed as mean ± standard deviation (n=5), and comparison between the two groups was performed by t-test.
Results There were no obvious fissures between spermatogenic cells in spermatogenic tubules of testis in both groups. In the control group and t group, 89.0%±12.9% and 63.5%±20.4%, respectively (the former ratio was significantly higher than the latter, P0.05), there were clusters of spermatogenic cells in the contours of the spermatogenic tubules. One side of the cluster was often not completely separated from the spermatogenic epithelium, as if part of the spermatogenic epithelium had a "C" shaped protruding into the lumen. The cell mass was mainly composed of sperm cells and pachytene spermatocyte, and the cell morphology was basically normal without obvious degeneration or pyrosis. Sertoli nuclei were present in 9.0%±8.3% and 33.6%±18.8% cell masses in both groups (the former ratio was significantly lower than the latter), respectively. The number of spermatogenic cells in spermatogenic tubules decreased in testosterone heptanate group, and some spermatogenic tubules even contained Sertoli cells and type A spermatogonial cells. The more severe the inhibition of spermatogenesis, the smaller and rarer the cell masses tend to be. FIG. 1 typical spermatogenic tubules in control group (a) and testosterone heptanate group (b), taken from 25m thick slices of methacrylate resin. Spermatogenic cell mass protruding into lumen. Scale = 5 on.
Heptanoic acid testosterone
Heptanoic acid testosterone
Discuss the author Zhengwei etc. Previous research shows that one of heptanoic acid testosterone group of 4 out of 5 there is no sperm in semen and but no abnormalities in the sperm number of sperm cells, testicular volume decreased by 28% on average, gave birth to the volume of seminiferous tubule decreased by 33% (compared with the control group), type A spermatagonial cells in the testes no significant change in total, However, the total number of type B spermatogonial cells decreased by 90%, the total number of other late spermatogenic cells decreased by 82% to 94%, the late (7-8) long spermatogenic cells retained, and the ratio of late spermatogenic cells to middle (3-6) spermatogenic cells increased by nearly 3 times. The supplementary study further showed that there were no obvious fissures between spermatogenic cells in spermatogenic tubules and no obvious loose arrangement of spermatogenic cells in both groups. This further supports the previous conclusion: heptanoic acid testosterone to gonadotropin and testicular heptanoic acid in testosterone retreat mainly by "double suppress" suppression of spermatogenesis, simultaneous suppression of spermatogenesis process starting stage (conversion to type B SSCS) and the terminal stage (late release of sperm cells), raw sperm cells arranged loose or fall off is not A key characteristics. However, the mechanism of why inhibition of T heptanate in rat testis results in apparent spermatogenic cell arrangement or shedding is still unclear. The degree of inhibition of testosterone heptanate in the testis, or the difference in sensitivity of the junctions between spermatogenic and sertoli cells to hormone withdrawal, may be a factor. Species differences in hormonal alterations may also be a factor.
Example of editing voice
For example, in adults, extraneous TESTOSTERONE heptanoid-induced testosterone withdrawal is associated with severe inhibition of FSH, but not with significant inhibition of FSH in rats '". In addition, treatment with ethane dimethylate (EDS) almost completely destroyed Leydig cells in rats (and thus almost completely suppressed testosterone heptanate levels in testis) and fed back with increased FSH levels. The withdrawal of T heptanate in testis may result in loose or abrogated spermatogenic cell arrangement in both humans and rats, but due to the severe inhibition of HUMAN FSH, early spermatogenic cell production is reduced and the phenomenon of loose or abrogated spermatogenic cell arrangement is not obvious. In rats, however, as FSH is not inhibited or even elevated, early spermatogenic cells continue to be produced in large numbers, so loose spermatogenic cells or shedding will be apparent. (Note: FSH partially maintains spermatogenesis to the round sperm cell stage '".) Another possible factor is that the combination of spermatogenic tubules (stages of spermatogenic cells) is spirally distributed in the spermatogenic tubules rather than segmentally distributed in rats, and it seems intuitive that segmentally distributed spermatogenic clumps may be more likely to split apart. The supplemental study also showed that most spermatogenic tubules (spermatogenic tubules equivalent to most of their length) were characterized by spermatogenic cell clusters protruding into the lumen without significant degeneration or pyknosis in the tubules, both in the TESTOSTERONE heptanate group and in the control group. The reason or significance of this phenomenon needs further analysis. Since this was seen in both groups, it is unlikely that the phenomenon seen in the T heptanate group was due to testosterone withdrawal in the testes. Clusters of spermatogenic cells were also found in 8% of the spermatogenic tubules after inhibition of TESTOSTERONE heptanate (not in the control group), but these clusters often had significantly pyknotic nuclei.
One possibility is that this phenomenon is related to the helical distribution of stages (combinations of cells) of spermatic epithelium. In testicular biopsy, a small incision is made in the capsule of the testicle, which allows the spermatogenic tubules to protrude (actually "extrude" due to high pressure in the testicle). In this process, spermatogenic tubules are bound to be deformed, and may cause the wall of spermatogenic tubules to fold and cause spermatogenic cell clusters protruded to the lumen. This is also a possible explanation, supported by the fact that a small number of Sertoli nuclei can be seen in spermatogenic cell masses in some spermatogenic tubules. If this explanation is true, it raises the important question of not treating this phenomenon as an anomaly in clinicopathological examination using testicular biopsy fragments.
Shipping method :
DHLFEDEXTNTUPSEMS
How to make an order :
1. Name what your need ( which product , quantity )
2. Full payment would be done once we come to an agreement on all details .
3. Parcel would be shipped out upon receipt of payment .
4. Info about parcel would be offered ( Photo , tracking number )
5. Finally you would get the parcel in 3~7 days .
Other Product:
Series | English Name | CAS NO. | Treatment effect |
Macitentan Series | Macitentan API | 441798-33-0 | ActelionPharmaceuticalsInc( PAH) |
2-(4-Bromo-phenyl)-malonic acid dimethyl este | 149506-35-4 | ||
5-(4-Bromophenyl)-4,6-pyrimidinediol | 706811-25-8 | ||
5-(4-Bromophenyl)-4,6-pyrimidinediol | 147962-41-2 | ||
5-(4-Bromophenyl)-4,6-dichloropyrimidine;PyriMidine, 5-(4-broMophenyl)-4,6-dichloro- | 146533-41-7 | ||
Brexpiprazole Series | Brexpiprazole API | 913611-97-9 | Antidepressant |
1-benzo[b]thien-4-yl-, hydrochloride | 913614-18-3 | ||
7-Hydroxyquinolinone | 70500-72-0 | ||
1-BOC-PIPERAZINE | 57260-71-6 | ||
(2E)-N-(3-Methoxyphenyl)-3-phenyl-2-propenamide | 127033-74-3 | ||
Lurasidone Series | Lurasidone API | 367514-87-2 | Nervous system drugs |
(R,R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane | 186204-35-3 | ||
(3aR,7aR)-4'-(1,2-Benzisothiazol-3-yl)octahydrospiro[2H-isoindole-2,1'-piperaziniuM] Methanesulfonate | 186204-37-5 | ||
(3aR,4S,7R,7aS) 4,7-Methano-1H-isoindole-1,3(2H)-dione | 14805-29-9 | ||
(1R,2R)-(-)-1,2-CYCLOHEXANEDICARBOXYLIC ACID | 46022-05-3 | ||
Etizolam Series | Etizolam API | 40054-69-1 | Antidepressant |
2-Amino-3-o-chlorobenzoyl-5-ethylthiophene | 50508-60-6 | ||
2-(Aminoacetylamino)-3-(o-chlorobenzoyl)-5-ethylthiophene | 50509-09-6 | ||
Baricitinib Series | Baricitinib API | 1187594-09-7 | Rheumatoidarthritis (RA) |
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)-methyl)-7h-pyrrolo[2,3-d]pyrimidine | 941685-27-4 | ||
2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile | 1187595-85-2 | ||
1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1029716-44-6 | ||
[4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate | 1146629-77-7 | ||
1-Boc-3-(cyanomethylene)azetidine | 1153949-11-1 | ||
Apixaban Series | Apixaban API | 503612-47-3 | Thromboprophylaxis |
3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-on | 545445-44-1 | ||
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone | 503615-03-0 | ||
4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl este | 536759-91-8 | ||
1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone | 1267610-26-3 | ||
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester | 503614-91-3 | ||
ethyl 6-(4-aMinophenyl)-1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate | 503615-07-4 | ||
Acetic acid, 2-chloro-2-[2-(4-methoxyphenyl)hydrazinylidene], ethyl ester | 27143-07-3 | ||
Others | Nintedanib intermediates | 2653-16-9 | IPF |
Ipragliflozin intermediates | 1034305-17-3 | Type 2 Diabetes | |
Tadalafil | 171596-29-5 | Sex Enhancement | |
Bupropion HCL | 31677-93-7 | Antidepressant |
Contact Person: sales
Tel: +8613777515435
CAS 112809-51-5 Letrozole Femara For Infertility Treatment USP42 Standard
82640-04-8 Active Pharmaceutical Ingredient API Raloxifene Hydrochloride HCL
Desloratadine Active Pharmaceutical Ingredient API 100643-71-8 For Relief Allergic Rhinitis
Antifungal Antibiotic API Miconazole Nitrate For Yeast Infecti 22832-87-7
C14H10Cl2NNaO2 Antibiotic API 15307-79-6 Diclofenac Sodium For Headache
T4 Clenbuterol Weight Loss Powder CAS 21898-19-1 White Crystalline Powder
846589-98-8 Lorcaserin Hydrochloride Steroids Fat Loss
99% Purity Follistatin 344 Bodybuilding Peptide Raw Powder Strong Effect 96829-58-2